Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

Exclusion Criteria

• •1. Older than 65 years of age for the primary series vaccination (able to receive booster doses if no other contraindications).
• •2. Clinically significant abnormal lab results, including evidence of Hepatitis C, Hepatitis B carrier state, or elevated (2 times normal) liver function tests.
• •3. Personal history of immunodeficiency or current treatment with immunosuppressive medication.
• •4. Confirmed positive human immunodeficiency virus (HIV) titer.
• •5. Any medical condition that, at the discretion of the physician, may jeopardize the safety of the subject.
• •6. Any serious or life-threatening allergies to any component of the vaccine: formalin human serum albumin neomycin streptomycin fetal rhesus lung cells RVF virus inactivated
• •7. Administration of any Investigational New Drug (IND) product or any vaccine within the 28 days before RVF vaccination.
• •8. Any unresolved adverse event resulting from a previous immunization.